Evidence map›Paper›PMID 38876119›Full record

ArticleInternational journal of immunopathology and pharmacology

Deucravacitinib and shikonin combination therapy ameliorates imiquimod-induced psoriasis in mice.

Ling Xu, Ying Jiang, Fuping Xu, Jun Liu, Yuhong Jiang, Fang Fang, Lin Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ling XuSchool of Pharmacy, Nantong University, Nantong, China.
Ying JiangSchool of Pharmacy, Nantong University, Nantong, China.
Fuping XuBiomarker Department, Crown Bioscience, Inc, Suzhou, China.
Jun LiuSchool of Pharmacy, Nantong University, Nantong, China.
Yuhong JiangBiomarker Department, Crown Bioscience, Inc, Suzhou, China.
Fang FangBiomarker Department, Crown Bioscience, Inc, Suzhou, China.
Lin LuoSchool of Pharmacy, Nantong University, Nantong, China.ORCID 0000-0002-7680-3518

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTYK2 inhibitors and traditional natural drugs as promising drugs for psoriasis therapy are receiving increasing attention. They both affect different molecules of JAK/STAT pathway, but it is currently unclear whether their combination will enhance the effect on psoriasis. In this study, we used imiquimod (IMQ)-induced psoriasis mouse model to investigate the therapeutic effects of the combined administration of deucravacitinib (TYK2 inhibitor) and shikonin.

methodsAldara cream containing 5% IMQ was used to topically treat the dorsal skin of each mouse for a total of six consecutive days to induce psoriasis. The psoriasis area and severity index (PASI) scores were recorded every day. On the 7

resultsCompared to the vehicle control group, the psoriasis symptoms and immune disorder improved significantly in the combination therapy group and deucravacitinib treatment group on the 7th day, and the expressions of p-STAT3 and Ki67 in skin were reduced as well. Moreover, the combined treatment of deucravacitinib and shikonin for psoriasis was superior to the monotherapy group, especially in inhibiting abnormal capillaries proliferation, reducing immune cells infiltration and decreasing the concentration of IL-12p70 in skin.

conclusionThe combination of deucravacitinib and shikonin is a promising clinical application.

Indexed as

Drug Therapy, CombinationImiquimodNaphthoquinonesPsoriasisSkinAnimalsBenzimidazolesCytokinesDisease Models, AnimalFemaleMaleMiceMice, Inbred BALB CQuinolones4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-oneBenzimidazolesCytokinesImiquimodNaphthoquinonesQuinolonesshikonincombination therapydeucravacitinibimiquimodpsoriasisshikonin

Identifiers

PMID38876119
PMCPMC11179549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.